Press release from Companies
Published: 2014-11-10 09:26:37
WntResearch AB announces that the Phase 1 trial has reached dose levels equivalent to the effective dose level in pre-clinical models with no dose limiting toxicity observed. Therefore, the company has decided to limit the enrollment of patients to those patients with highest likelihood to respond to Foxy-5. This means that we will limit the enrollment to prostate-, colon- and breast cancer patients with no or low level of Wnt-5a expression at our two sites at the Herlev University Hospital and the Rigshospitalet, Phase 1 Unit in Copenhagen. Consequently, the completion of the study is expected to be postponed from Q4 2014 to Q1 2015.
VD Nils Brünner comments: “We have now reached dose levels where our pre-clinical work indicates that Foxy-5 may be effective in patients. I’m pleased that we have not seen any dose limiting toxicities and that we can focus the inclusion of patients to those who we expect will have the highest likelihood of response. We acknowledge that the patient pool will be reduced because of this. Therefore, I am pleased to welcome the Rigshospitalet, Phase 1 Unit, who has dosed the first patient and now participates in the Foxy-5 Phase 1 dose escalation study together with Herlev University Hospital to find the optimal dose for Phase 2.” For additional information please contact: Nils Brünner, VD E-mail: email@example.com Telephone: + 45 2614 4708 About WntResearch WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase I – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.